Medical science has made remarkable advances in gastrointestinal disease research and treatment over the past two decades and AstraZeneca has played a significant role in many of these advances. More than 20 million Canadians suffer from digestive disorders every year and an average of five million Canadians experience heartburn at least once a week.
Thanks to the discovery of the correlation between infection and ulcers, as well as the development of proton pump inhibitors, physicians today are able to effectively treat individuals who suffer from gastrointestinal disease.